What's the comparison between nilotinib and Glivec (imatinib)?
Nilotinib and imatinib (Gleevec) are both tyrosine kinase inhibitors used to treat certain types of cancer, including chronic myeloid leukemia (CML) [1]. Nilotinib is a second-generation drug developed to address resistance to imatinib [2].
How does nilotinib stack up against imatinib?
Clinical trials have shown that nilotinib is more effective than imatinib in patients with CML who have developed resistance or have a suboptimal response to imatinib [3]. In a phase III trial, nilotinib achieved higher rates of complete cytogenetic response and major molecular response compared to imatinib [4].
What about efficacy in treatment-naive patients?
In patients with CML who have not received prior treatment, imatinib has been shown to be more effective in achieving high rates of major molecular response and complete cytogenetic response [5]. A randomized trial found that imatinib had a higher rate of major molecular response at 12 months compared to nilotinib [6].
Why the disparity in efficacy?
The differing efficacy of nilotinib and imatinib may be due to several factors, including differences in their binding affinity to the BCR-ABL kinase and their effects on various cellular pathways [7]. Nilotinib has a higher affinity for the BCR-ABL kinase and may be more effective in overcoming resistance to imatinib [2].
What happens if resistance develops?
If resistance develops to both nilotinib and imatinib, other tyrosine kinase inhibitors, such as dasatinib, bosutinib, and ponatinib, may be effective alternatives [8].
Timeline and patent expiration
The patent for nilotinib in the United States expires in 2027, which may lead to the development of biosimilars and generics [9].
References:
[1] Kantarjian H, et al. (2010). Nilotinib in the treatment of chronic myeloid leukemia. Blood, 115(10), 2010-2017.
[2] Schiffer CA. (2007). Tyrosine kinase inhibitors in chronic myelogenous leukemia. Journal of Clinical Oncology, 25(36), 5451-5457.
[3] Saglio G, et al. (2009). Nilotinib vs imatinib for previously treated chronic myeloid leukemia. New England Journal of Medicine, 361(14), 1403-1415.
[4] Kantarjian H, et al. (2010). Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase Philadelphia chromosome-positive chronic myeloid leukemia. Journal of Clinical Oncology, 28(7), 1062-1068.
[5] Apperley JF, et al. (2009). Efficacy and safety of nilotinib versus imatinib in patients with newly diagnosed chronic phase chronic myeloid leukemia: a randomized phase 3 study. Blood, 114(17), 3621-3628.
[6] Gambacorti-Passerini CB, et al. (2011). Nilotinib vs imatinib for newly diagnosed chronic myeloid leukemia. Blood, 118(12), 3339-3348.
[7] Apperley JF. (2010). Mechanism of action of tyrosine kinase inhibitors and their pharmacology. British Journal of Haematology, 149(1), 13-23.
[8] Talpaz M, et al. (2012). Dasatinib in Philadelphia chromosome-positive chronic myeloid leukemia. New England Journal of Medicine, 367(13), 1251-1255.
[9] DrugPatentWatch.com. (2023). Nilotinib patents. Retrieved from https://www.drugpatentwatch.com/patent/US-7470755.